SINT vs. NEPH, PYPD, IINN, LUCY, LFWD, LYRA, SSKN, CTCX, QTI, and BTCY
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include Nephros (NEPH), PolyPid (PYPD), Inspira Technologies Oxy B.H.N. (IINN), Innovative Eyewear (LUCY), ReWalk Robotics (LFWD), Lyra Therapeutics (LYRA), STRATA Skin Sciences (SSKN), Carmell (CTCX), QT Imaging (QTI), and Biotricity (BTCY). These companies are all part of the "medical equipment" industry.
Sintx Technologies vs.
Sintx Technologies (NASDAQ:SINT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 0.0% of Sintx Technologies shares are owned by company insiders. Comparatively, 4.1% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sintx Technologies has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
In the previous week, Sintx Technologies had 1 more articles in the media than Nephros. MarketBeat recorded 1 mentions for Sintx Technologies and 0 mentions for Nephros. Sintx Technologies' average media sentiment score of 0.00 equaled Nephros'average media sentiment score.
Nephros has a net margin of -6.86% compared to Sintx Technologies' net margin of -358.79%. Nephros' return on equity of -11.39% beat Sintx Technologies' return on equity.
Nephros has higher revenue and earnings than Sintx Technologies. Nephros is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Nephros has a consensus target price of $5.00, indicating a potential upside of 212.50%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Sintx Technologies.
Sintx Technologies received 23 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 61.02% of users gave Sintx Technologies an outperform vote while only 43.33% of users gave Nephros an outperform vote.
Summary
Nephros beats Sintx Technologies on 11 of the 17 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sintx Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:SINT) was last updated on 1/21/2025 by MarketBeat.com Staff
